medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2012, Number 2

<< Back Next >>

Rev Esp Med Quir 2012; 17 (2)

Brain dysfunction in addictions

Aguilar BOE, Mendoza MMÁ, Valdez GGR, López BMÁ, Camacho SR

Language: Spanish
References: 28
Page: 119-124
PDF size: 374.53 Kb.


ABSTRACT

There is a close relationship between drug addiction and brain function. Some genetic features affect brain function representing a vulnerability factor on the development of addictions. Drug addiction has harmful consequences on brain function, especially on executive function. Whatever is the cause of alteration on executive functions may represent a vulnerability factor for drug addiction. Long-term drug consumption alters neuropsychological function, so neuropsychological rehabilitation must be a core issue in drug addiction treatment.


REFERENCES

  1. National Institute on Drug Abuse. Principios de tratamientos para la drogadicción. Una guía basada en las investigaciones. Maryland: NIDA; 2010.

  2. Wan YJ, Poland RE, Lin KM. Genetic polymorphism of CYP2E1, ADH2, and ALDH2 in Mexican-Americans. Genet Test 1998;2:79-83.

  3. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genom Hum Genet 2001;2:9-39.

  4. Wu X, Hudmon KS, Detry MA, Chamberlain RM, Spitz MR. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:1021-1026.

  5. Madrid GA, MacMurray J, Lee JW, Anderson BA, Comings DE. Stress as a mediating factor in the association between the DRD2 Taq I polymorphism and alcoholism. Alcohol 2001;23:117-122.

  6. Konishi T, Luo HR, Calvillo M, Mayo MS, et al. ADH1B*1, ADH1C*2, DRD2 (−141C Ins), and 5-HTTLPR are associated with alcoholism in Mexican-American men living in Los Angeles. Alcohol Clin Exp Res 2004;28:1145-1152.

  7. Cigler T, LaForge KS, McHugh PF, Kapadia SU, et al. Novel and previously reported single-nucleotide polymorphisms in the human 5-HT (1B) receptor gene: no association with cocaine or alcohol abuse or dependence. Am J Med Genet 2001;105:489-497.

  8. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 1999;146:373-390.

  9. Purves D. Emotion. In: Purves D, Augustine G, Fitzpatrick D, Hall W, editors. Neuroscience. Sunderland, MA: Sinauer Associates, Inc., 2004.

  10. Hitchcott PK, Harmer CJ, Phillips GD. Enhanced acquisition of discriminative approach following intra-amygdala d-amphetamine. Psychopharmacology 1997;132:237-246.

  11. Schoenbaum G, Roesch MR, Stalnaker TA. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci 2006;29(2):116-124.

  12. Bechara A, Dolan S, Hindes A. Decision-making and addiction. Part II: Myopia for the future or hypersensitivity to reward? Neuropsychologia 2002;40:1690-1705.

  13. Bechara A, Dolan S, Denburg N, Hindes A, et al. Decisionmaking deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia 2001;9:376-389.

  14. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642-1652.

  15. Crews FT, Boettiger C. Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 2009;93(3):237-247.

  16. Scolaro R, Franz C. The neuropsychological consequences of alcohol and drug abuse. In: Brick J, editor. Handbook of the medical consequences of alcohol and drug abuse. New York: The Haworth Press, 2004.

  17. Chirivella J, Espert R, Gadea M. Déficits neuropsicológicos asociados al consumo de alcohol. Una aproximación multidisciplinar. Psicología Conductual 1996;3:377-392.

  18. Collaut R, Arbizia I, Arrúe R, Collaut J, Bajo R. Deterioro cognitivo asociado al consumo de diferentes sustancias psicoactivas. Actas Esp Psiquiatr 2011;39(3):168-173.

  19. Jacobus J, Bava S, Cohen-Zion M, Mahmood O, Tapert, SF. Functional consequences of marijuana use in adolescents. Pharmacol Biochem Behav 2009;92(4):559-565.

  20. Woicik P, Moeller S, Alia-Klein S, Maloney T, et al. The neuropsychology of cocaine addiction: recent cocaine use masks impairment. Neuropsychopharmacology 2009;34(5):1112-1122.

  21. Iudicello J, Woods S, Vigil O, Scott J, et al and The Hiv Neurobehavioral Research Center (HNRC) Group. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. Clin Exp Neuropsychol 2010;32(7):704-718.

  22. Filley CM, Heaton RK, Rosenberg NL. White matter dementia in chronic toluene abuse. Neurology 1990;40(3):532-534.

  23. Uitti RJ, Snow BJ, Shinotoh H, Vingerhoets FJ, et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994; 35:616-619.

  24. Kolb B, Whishaw IQ. Fundamentals of human neuropsychology. 5th ed. New York: Worth Publishers, 2004.

  25. National Institute on Drug Abuse Developing Behavioral Treatments for Drug Abusers with Cognitive Impairments. 2003. Recuperado el 6 de septiembre de 2011 de: http://archives.drugabuse.gov/meetings/cognitiveimpairment.html

  26. Bickel WR, Yi R, Landes R, Hill P, Baxter C. Remember the future: working memory training decreases delay discounting among stimulant addicts. Biol Psychiatry 2011;69;260-265.

  27. Fals-Stewart W, Lam WK. Computer-assisted cognitive rehabilitation for the treatment of patients with substance use disorders: A randomized clinical trial. Exp Clin Psychopharmacol 2010;18:87-98.

  28. Goldstein G, Hass G, Shemansky W, Barnett B, Salmon-Cox S. Rehabilitation during alcohol detoxication in comorbid neuropsychiatric patients. JRRD 2005;42(2):225-234.




2020     |     www.medigraphic.com